Biologics in systemic autoimmune diseases during COVID-19 pandemic.
作者信息
Annapureddy Narender, Nalleballe Krishna, Onteddu Sanjeeva Reddy, Sharma Rohan, Sheng Sen, Kovvuru Sukanthi, Siddamreddy Suman, Mandhadi Ranadeep
机构信息
Department of Rheumatology, Vanderbilt University, Nashville, TN, USA.
Department of Neurology, University of Arkansas for Medical Sciences, 4301 W. Markham St #500, Little Rock, AR, 72205-7199, USA.
出版信息
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
Abstract
摘要
相似文献
1
Biologics in systemic autoimmune diseases during COVID-19 pandemic.新冠疫情期间系统性自身免疫性疾病中的生物制剂
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
2
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
3
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.基线疾病活动度和类固醇治疗对炎症性肠病患者感染新型冠状病毒肺炎的风险进行分层。
Gastroenterology. 2020 Oct;159(4):1541-1544.e2. doi: 10.1053/j.gastro.2020.05.066. Epub 2020 May 29.
4
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.2019 年冠状病毒病（COVID-19）在自身免疫和炎症性疾病中的表现：不良结局的临床特征。
Rheumatol Int. 2020 Oct;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4. Epub 2020 Aug 13.
5
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series.COVID-19 与风湿性自身免疫性系统性疾病：一项大型意大利患者系列报告。
Clin Rheumatol. 2020 Nov;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7. Epub 2020 Aug 27.
6
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
7
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
8
What is the true incidence of COVID-19 in patients with rheumatic diseases?风湿性疾病患者中新型冠状病毒肺炎的真实发病率是多少？
Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.
9
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
10
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
引用本文的文献
1
Impact of the COVID-19 pandemic on inflammatory bowel disease care in Taiwan: A multicenter study.COVID-19 大流行对台湾炎症性肠病治疗的影响：一项多中心研究。
J Formos Med Assoc. 2023 Oct;122(10):1042-1049. doi: 10.1016/j.jfma.2023.03.017. Epub 2023 Mar 27.
2
Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.生物制剂和小分子药物对炎症性肠病患者COVID-19相关住院率和死亡率的影响：一项系统评价和荟萃分析
JGH Open. 2022 Mar 20;6(4):241-250. doi: 10.1002/jgh3.12728. eCollection 2022 Apr.
3
Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.冠状病毒病（COVID-19）大流行期间皮下注射英夫利昔单抗（CT-P13 SC）治疗强直性脊柱炎患者的真实世界证据：病例系列
Clin Case Rep. 2022 Jan 13;10(1):e05233. doi: 10.1002/ccr3.5233. eCollection 2022 Jan.
4
COVID-19 illness and autoimmune diseases: recent insights.COVID-19 疾病与自身免疫性疾病：最新见解。
Inflamm Res. 2021 Apr;70(4):407-428. doi: 10.1007/s00011-021-01446-1. Epub 2021 Feb 28.
本文引用的文献
1
Spectrum of neuropsychiatric manifestations in COVID-19.新型冠状病毒肺炎的神经精神表现谱。
Brain Behav Immun. 2020 Aug;88:71-74. doi: 10.1016/j.bbi.2020.06.020. Epub 2020 Jun 17.
2
Spectrum of COVID-19 in children.儿童新型冠状病毒肺炎的疾病谱
Acta Paediatr. 2020 Sep;109(9):1899-1900. doi: 10.1111/apa.15412. Epub 2020 Jul 30.
3
Underutilization of health care for strokes during the COVID-19 outbreak.2019冠状病毒病疫情期间中风医疗服务利用不足。
Int J Stroke. 2020 Jul;15(5):NP9-NP10. doi: 10.1177/1747493020934362. Epub 2020 Jun 18.
4
Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?新冠病毒感染中针对过度炎症反应的免疫抑制：一把双刃剑？
Lancet. 2020 Apr 4;395(10230):1111. doi: 10.1016/S0140-6736(20)30691-7. Epub 2020 Mar 24.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.与类风湿关节炎相关的感染风险，及其合并症和治疗。
Rheumatology (Oxford). 2013 Jan;52(1):53-61. doi: 10.1093/rheumatology/kes305. Epub 2012 Nov 28.
7
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.高疾病活动度与类风湿关节炎患者的感染风险增加有关。
Ann Rheum Dis. 2011 May;70(5):785-91. doi: 10.1136/ard.2010.128637. Epub 2011 Feb 2.
Zotero 插件